Patents Assigned to University Court of the University of Dundee
  • Patent number: 11123100
    Abstract: An ultrasonically actuated medical implement is used in improving medical interventions and in certain instances to the generation of image data, in particular data acquired during a medical intervention or procedure. The medical implement employs a piezoelectric element which causes reciprocation between first and second mass assemblies in order to ultrasonically actuate a probe member and improve the visibility of the probe member to imaging methods. The invention also concerns the visibility of structures in target regions to be imaged and how this may be enhanced using the medical implement of the invention.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: September 21, 2021
    Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE
    Inventors: Muhammad Sadiq, Sandy Cochran, Zhihong Huang, George Corner, Graeme McLeod, Patrick Carena
  • Patent number: 10829799
    Abstract: The present invention relates to the production of activated biological molecules for use in profiling biological molecule interactions. The activated biological molecule may be a ubiquitin (Ub) and ubiquitin-like conjugation enzyme as well as other proteins with internal reactive cysteine residues.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: November 10, 2020
    Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE
    Inventors: Satpal Virdee, Mathew Stanley, Kuan-Chuan Pao
  • Patent number: 10233157
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: March 19, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., University Court of the University of Dundee
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
  • Publication number: 20180215719
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Application
    Filed: May 26, 2017
    Publication date: August 2, 2018
    Applicants: Dana-Farber Cancer Institute, Inc., University Court of the University of Dundee
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
  • Patent number: 9919060
    Abstract: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: March 20, 2018
    Assignee: University Court of the University of Dundee
    Inventors: Steven Albert Everett, Saraj Ulhaq
  • Publication number: 20170342036
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., University Court of the University of Dundee
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
  • Patent number: 9670165
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 6, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., University Court of the University of Dundee
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael Gray
  • Publication number: 20160242811
    Abstract: The invention relates to improving medical interventions and in certain instances to the generation of image data, in particular data acquired during a medical intervention or procedure. The invention also concerns the visibility of structures in target regions to be imaged and how this may be enhanced.
    Type: Application
    Filed: March 11, 2014
    Publication date: August 25, 2016
    Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE
    Inventors: Muhammad Sadiq, Sandy Cochran, Zhihong Huang, George Corner, Graeme McLeod, Patrick Carena
  • Patent number: 9365508
    Abstract: The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar? are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: June 14, 2016
    Assignees: University Court of the University of St Andrews, University Court of the University of Dundee
    Inventors: Sonia Lain, Nicholas James Westwood, David Philip Lane
  • Patent number: 9265826
    Abstract: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: February 23, 2016
    Assignee: University Court of the University of Dundee
    Inventors: Paul Richard Crocker, Bjoern Biedermann, David Bowen
  • Publication number: 20160000908
    Abstract: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.
    Type: Application
    Filed: March 12, 2013
    Publication date: January 7, 2016
    Applicant: University Court of the University of Dundee
    Inventors: Paul Richard Crocker, Bjoern Biedermann, David Bowen
  • Patent number: 9155289
    Abstract: Non-human animals which overexpress PPARd or which express transgenic PPARd are useful as models for inflammatory skin conditions such as psoriasis. Test substances can be screened to assess their suitability for the treatment of inflammatory skin conditions such as psoriasis. Methyl 3-({[2-(methoxy)-4-phenyl]amino}sulfonyl)-2-thiophenecarboxylate can be administered topically for the prevention or treatment of psoriasis.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: October 13, 2015
    Assignee: University Court of the University of Dundee
    Inventors: Colin Palmer, John Foerster, Nainamalai Sitherswaran
  • Patent number: 9120765
    Abstract: The present invention relates to compounds which activate the p53 response, and find use in, for example, hyperproliferative diseases such as cancer treatment and potentially other diseases/conditions involving sirtuin function.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: September 1, 2015
    Assignees: University Court of the University of Dundee, University Court of the University of St. Andrews
    Inventors: Sonia Lain, David Phillip Lane, Michael John Raymond Stark, Anna Rose McCarthy, Jonathan James Hollick, Nicholas James Westwood
  • Patent number: 9050374
    Abstract: The present invention relates to a multi-functional protease inhibitor, which may be conjugated to various molecules. The present invention also relates to uses of the protease inhibitor and conjugates thereof.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: June 9, 2015
    Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE
    Inventors: Colin Watts, Sander Van Kasteren
  • Patent number: 8999635
    Abstract: The present invention relates to the identification of loss-of-function mutations in the filaggrin gene and their use in diagnosing ichthyosis vulgaris and/or susceptibility to other diseases including atopic dermatitis (eczema), asthma, psoriasis and allergies (including food allergy).
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: April 7, 2015
    Assignee: University Court of The University of Dundee
    Inventors: William Henry Irwin McLean, Frances Jane Dorothy Smith
  • Publication number: 20130302317
    Abstract: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.
    Type: Application
    Filed: March 12, 2013
    Publication date: November 14, 2013
    Applicant: University Court of the University of Dundee
    Inventors: Paul Richard Crocker, Bjoern Biedermann, David Bowen
  • Patent number: 8563557
    Abstract: The invention provides a compound according to formula (I): wherein: X is O or S; Y is O or S; each Ar and Ar? is independently a mono-, bi- or tricyclic aryl or heteroaryl group optionally substituted with one or more substituents selected from halo, alkyl, aryl, heteroaryl, hydroxyl, nitro, amino, alkoxy, alkylthio, cyano, thio, ester, acyl and amido; each R2 is independently hydrogen, halo, alkyl, aryl, heteroaryl, hydroxyl, nitro, amino, alkoxy, alkylthio, cyano and thio; and R1 is as defined herein, or a physiologically acceptable salt, solvate, ester, amide or other physiologically functional derivative thereof.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: October 22, 2013
    Assignees: University Court of the University of Dundee, University Court of the University of St Andrews
    Inventors: Nicholas James Westwood, Sonia Lain, Federico Medda
  • Patent number: 8512760
    Abstract: A process for the production of an aqueous dispersion of metal nano particles comprising palladium is provided. The process comprises the admixture of a water soluble organic polymer, a palladium salt and a first reducing agent to an aqueous liquid. The first reducing agent is a metal-containing polymer which has reducing properties or a saccharide which has reducing properties. The nano particles can include a second metal. The dispersions can be used as catalysts for electroless plating, to produce heterogeneous catalysts and in the production of anti-microbial devices and compositions.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: August 20, 2013
    Assignee: The University Court of the University of Dundee
    Inventors: James Anthony Cairns, Roderick Allan George Gibson, Graham James Berry
  • Patent number: 8501991
    Abstract: The present invention relates to compounds which activate the p53 response, and find use in, for example, hyperproliferative diseases such as cancer treatment and potentially other diseases/conditions (involving sirtuin function).
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: August 6, 2013
    Assignees: University Court of the University of Dundee, University Court of the University of St. Andrews
    Inventors: Sonia Lain, David Phillip Lane, Michael John Raymond Stark, Anna Rose McCarthy, Jonathan James Hollick, Nicholas James Westwood
  • Publication number: 20130131102
    Abstract: The present invention provides glucoimidazole derivatives and methods of making them. The compounds can be used to inhibit the activity of O-GlcNAcase enzymes, including both bacterial OGA (bOGA) and human OGA (hOGA) and can be selective, showing low inhibition of hexosaminidases. The compounds can be used to study the role of the O-GlcNAcase modification in human or animal cells. Furthermore the compounds can have therapeutic uses in the treatment of diseases mediated by the activity of O-GlcNAcase enzymes including type II diabetes, Alzheimers Disease, and cancer.
    Type: Application
    Filed: November 13, 2012
    Publication date: May 23, 2013
    Applicant: The University Court of the University of Dundee
    Inventor: The University Court of the University of Dundee